All data are based on the daily closing price as of April 1, 2025
e

Eisai

4523.TSE
27.44 USD
-0.36
-1.29%

Overview

Last close
27.44 usd
Market cap
7.74B usd
52 week high
53.00 usd
52 week low
26.73 usd
Target price
34.58 usd

Valuation

P/E
20.1773
Forward P/E
32.6797
Price/Sales
1.5422
Price/Book Value
1.3389
Enterprise Value
7.33B usd
EV/Revenue
1.3849
EV/EBITDA
8.9465

Key financials

Revenue TTM
5.29B usd
Gross Profit TTM
4.19B usd
EBITDA TTM
707.96M usd
Earnings per Share
1.38 usd
Dividend
1.07 usd
Total assets
9.17B usd
Net debt
-461.66M usd

About

Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan. It offers Dayvigo, for the treatment of insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; Methycobal for the treatment of peripheral neuropathy; and Halaven, an anticancer agent for the treatment of breast cancer. The company also provides Jyseleca, a janus kinase inhibitor; Elental, a branched-chain amino acid preparation; Goofice and Movicol for chronic constipation; Fycompa, an antiepileptic agent; Pariet, a proton-pump inhibitor; Aricept, for Alzheimer's disease/Dementia with Lewy bodies; and Chocola BB plus for the preparation vitamin B2. It has strategic collaboration with Bristol Myers Squibb for the co-development and co-commercialization of farletuzumab ecteribulin antibody drug conjugate; and a clinical trial collaboration and supply agreement with Medivir for the evaluation of fostrox, a liver-targeted treatment. Eisai Co., Ltd. was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
  • Symbol
    4523.TSE
  • Exchange
    TSE
  • Isin
    JP3160400002
  • Country
    Japan
  • Sector
    Healthcare
  • Industry
    Drug Manufacturers - Specialty & Generic
  • CEO
    Mr. Haruo Naito
  • Headquarter
    Tokyo
  • Web site
    https://www.eisai.co.jp
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top